EGFR and non-small cell lung carcinoma: In 2019, an international clinical trial (OUTRUN; NCT03497767) was initiated to clarify whether upfront SRS plus osimertinib can improve intracranial disease control for EGFRm NSCLC patients with ≤10 de novo or developed brain metastases after first‐generation EGFR TKI therapy compared with osimertinib treatment alone.